Global Parkinson's Disease Treatments Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Parkinson's Disease Treatments market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Parkinson's Disease Treatments is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Parkinson's Disease Treatments is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Parkinson's Disease Treatments market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Parkinson's Disease Treatments is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Parkinson's Disease Treatments market include GSK, Teva, Sun Pharma, Novartis, Merck, Abbvie, Wockhardt, UCB and Lundbeck, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Parkinson's Disease Treatments, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Parkinson's Disease Treatments, also provides the value of main regions and countries. Of the upcoming market potential for Parkinson's Disease Treatments, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Parkinson's Disease Treatments revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Parkinson's Disease Treatments market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Parkinson's Disease Treatments company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Parkinson's Disease Treatments Segment by Company
GSK
Teva
Sun Pharma
Novartis
Merck
Abbvie
Wockhardt
UCB
Lundbeck
Impax
Boehringer Ingelheim
Bausch Health
Acadia
Parkinson's Disease Treatments Segment by Type
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Apomorphine
Dopamine Agonists
Glutamate Antagonist
Levodopa
Other Drugs
Parkinson's Disease Treatments Segment by Application
Hospitals
Healthcare Institutes
Others
Parkinson's Disease Treatments Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Parkinson's Disease Treatments status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Parkinson's Disease Treatments key companies, revenue, market share, and recent developments.
3. To split the Parkinson's Disease Treatments breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Parkinson's Disease Treatments market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Parkinson's Disease Treatments significant trends, drivers, influence factors in global and regions.
6. To analyze Parkinson's Disease Treatments competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson's Disease Treatments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parkinson's Disease Treatments and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson's Disease Treatments.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Parkinson's Disease Treatments industry.
Chapter 3: Detailed analysis of Parkinson's Disease Treatments company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Parkinson's Disease Treatments in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Parkinson's Disease Treatments in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Parkinson's Disease Treatments market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Parkinson's Disease Treatments is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Parkinson's Disease Treatments is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Parkinson's Disease Treatments market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Parkinson's Disease Treatments is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Parkinson's Disease Treatments market include GSK, Teva, Sun Pharma, Novartis, Merck, Abbvie, Wockhardt, UCB and Lundbeck, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Parkinson's Disease Treatments, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Parkinson's Disease Treatments, also provides the value of main regions and countries. Of the upcoming market potential for Parkinson's Disease Treatments, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Parkinson's Disease Treatments revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Parkinson's Disease Treatments market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Parkinson's Disease Treatments company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Parkinson's Disease Treatments Segment by Company
GSK
Teva
Sun Pharma
Novartis
Merck
Abbvie
Wockhardt
UCB
Lundbeck
Impax
Boehringer Ingelheim
Bausch Health
Acadia
Parkinson's Disease Treatments Segment by Type
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Apomorphine
Dopamine Agonists
Glutamate Antagonist
Levodopa
Other Drugs
Parkinson's Disease Treatments Segment by Application
Hospitals
Healthcare Institutes
Others
Parkinson's Disease Treatments Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Parkinson's Disease Treatments status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Parkinson's Disease Treatments key companies, revenue, market share, and recent developments.
3. To split the Parkinson's Disease Treatments breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Parkinson's Disease Treatments market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Parkinson's Disease Treatments significant trends, drivers, influence factors in global and regions.
6. To analyze Parkinson's Disease Treatments competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson's Disease Treatments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parkinson's Disease Treatments and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson's Disease Treatments.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Parkinson's Disease Treatments industry.
Chapter 3: Detailed analysis of Parkinson's Disease Treatments company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Parkinson's Disease Treatments in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Parkinson's Disease Treatments in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
196 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Parkinson's Disease Treatments Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Parkinson's Disease Treatments Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Parkinson's Disease Treatments Market Dynamics
- 2.1 Parkinson's Disease Treatments Industry Trends
- 2.2 Parkinson's Disease Treatments Industry Drivers
- 2.3 Parkinson's Disease Treatments Industry Opportunities and Challenges
- 2.4 Parkinson's Disease Treatments Industry Restraints
- 3 Parkinson's Disease Treatments Market by Company
- 3.1 Global Parkinson's Disease Treatments Company Revenue Ranking in 2024
- 3.2 Global Parkinson's Disease Treatments Revenue by Company (2020-2025)
- 3.3 Global Parkinson's Disease Treatments Company Ranking (2023-2025)
- 3.4 Global Parkinson's Disease Treatments Company Manufacturing Base and Headquarters
- 3.5 Global Parkinson's Disease Treatments Company Product Type and Application
- 3.6 Global Parkinson's Disease Treatments Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Parkinson's Disease Treatments Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Parkinson's Disease Treatments Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Parkinson's Disease Treatments Market by Type
- 4.1 Parkinson's Disease Treatments Type Introduction
- 4.1.1 COMT Inhibitors Anticholinergics
- 4.1.2 MAO-B Inhibitors
- 4.1.3 Apomorphine
- 4.1.4 Dopamine Agonists
- 4.1.5 Glutamate Antagonist
- 4.1.6 Levodopa
- 4.1.7 Other Drugs
- 4.2 Global Parkinson's Disease Treatments Sales Value by Type
- 4.2.1 Global Parkinson's Disease Treatments Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Parkinson's Disease Treatments Sales Value by Type (2020-2031)
- 4.2.3 Global Parkinson's Disease Treatments Sales Value Share by Type (2020-2031)
- 5 Parkinson's Disease Treatments Market by Application
- 5.1 Parkinson's Disease Treatments Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Healthcare Institutes
- 5.1.3 Others
- 5.2 Global Parkinson's Disease Treatments Sales Value by Application
- 5.2.1 Global Parkinson's Disease Treatments Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Parkinson's Disease Treatments Sales Value by Application (2020-2031)
- 5.2.3 Global Parkinson's Disease Treatments Sales Value Share by Application (2020-2031)
- 6 Parkinson's Disease Treatments Regional Value Analysis
- 6.1 Global Parkinson's Disease Treatments Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Parkinson's Disease Treatments Sales Value by Region (2020-2031)
- 6.2.1 Global Parkinson's Disease Treatments Sales Value by Region: 2020-2025
- 6.2.2 Global Parkinson's Disease Treatments Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Parkinson's Disease Treatments Sales Value (2020-2031)
- 6.3.2 North America Parkinson's Disease Treatments Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Parkinson's Disease Treatments Sales Value (2020-2031)
- 6.4.2 Europe Parkinson's Disease Treatments Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Parkinson's Disease Treatments Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Parkinson's Disease Treatments Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Parkinson's Disease Treatments Sales Value (2020-2031)
- 6.6.2 South America Parkinson's Disease Treatments Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Parkinson's Disease Treatments Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Parkinson's Disease Treatments Sales Value Share by Country, 2024 VS 2031
- 7 Parkinson's Disease Treatments Country-level Value Analysis
- 7.1 Global Parkinson's Disease Treatments Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Parkinson's Disease Treatments Sales Value by Country (2020-2031)
- 7.2.1 Global Parkinson's Disease Treatments Sales Value by Country (2020-2025)
- 7.2.2 Global Parkinson's Disease Treatments Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.7.2 France Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.14.2 China Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.17.2 India Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Parkinson's Disease Treatments Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Parkinson's Disease Treatments Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Parkinson's Disease Treatments Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 GSK
- 8.1.1 GSK Comapny Information
- 8.1.2 GSK Business Overview
- 8.1.3 GSK Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.1.4 GSK Parkinson's Disease Treatments Product Portfolio
- 8.1.5 GSK Recent Developments
- 8.2 Teva
- 8.2.1 Teva Comapny Information
- 8.2.2 Teva Business Overview
- 8.2.3 Teva Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.2.4 Teva Parkinson's Disease Treatments Product Portfolio
- 8.2.5 Teva Recent Developments
- 8.3 Sun Pharma
- 8.3.1 Sun Pharma Comapny Information
- 8.3.2 Sun Pharma Business Overview
- 8.3.3 Sun Pharma Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.3.4 Sun Pharma Parkinson's Disease Treatments Product Portfolio
- 8.3.5 Sun Pharma Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Comapny Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.4.4 Novartis Parkinson's Disease Treatments Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 Merck
- 8.5.1 Merck Comapny Information
- 8.5.2 Merck Business Overview
- 8.5.3 Merck Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.5.4 Merck Parkinson's Disease Treatments Product Portfolio
- 8.5.5 Merck Recent Developments
- 8.6 Abbvie
- 8.6.1 Abbvie Comapny Information
- 8.6.2 Abbvie Business Overview
- 8.6.3 Abbvie Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.6.4 Abbvie Parkinson's Disease Treatments Product Portfolio
- 8.6.5 Abbvie Recent Developments
- 8.7 Wockhardt
- 8.7.1 Wockhardt Comapny Information
- 8.7.2 Wockhardt Business Overview
- 8.7.3 Wockhardt Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.7.4 Wockhardt Parkinson's Disease Treatments Product Portfolio
- 8.7.5 Wockhardt Recent Developments
- 8.8 UCB
- 8.8.1 UCB Comapny Information
- 8.8.2 UCB Business Overview
- 8.8.3 UCB Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.8.4 UCB Parkinson's Disease Treatments Product Portfolio
- 8.8.5 UCB Recent Developments
- 8.9 Lundbeck
- 8.9.1 Lundbeck Comapny Information
- 8.9.2 Lundbeck Business Overview
- 8.9.3 Lundbeck Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.9.4 Lundbeck Parkinson's Disease Treatments Product Portfolio
- 8.9.5 Lundbeck Recent Developments
- 8.10 Impax
- 8.10.1 Impax Comapny Information
- 8.10.2 Impax Business Overview
- 8.10.3 Impax Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.10.4 Impax Parkinson's Disease Treatments Product Portfolio
- 8.10.5 Impax Recent Developments
- 8.11 Boehringer Ingelheim
- 8.11.1 Boehringer Ingelheim Comapny Information
- 8.11.2 Boehringer Ingelheim Business Overview
- 8.11.3 Boehringer Ingelheim Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.11.4 Boehringer Ingelheim Parkinson's Disease Treatments Product Portfolio
- 8.11.5 Boehringer Ingelheim Recent Developments
- 8.12 Bausch Health
- 8.12.1 Bausch Health Comapny Information
- 8.12.2 Bausch Health Business Overview
- 8.12.3 Bausch Health Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.12.4 Bausch Health Parkinson's Disease Treatments Product Portfolio
- 8.12.5 Bausch Health Recent Developments
- 8.13 Acadia
- 8.13.1 Acadia Comapny Information
- 8.13.2 Acadia Business Overview
- 8.13.3 Acadia Parkinson's Disease Treatments Revenue and Gross Margin (2020-2025)
- 8.13.4 Acadia Parkinson's Disease Treatments Product Portfolio
- 8.13.5 Acadia Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



